Silver Book Fact

Potential value of pneumonia vaccine

Use of PCV13 (13-valent pneumococcal conjugate vaccine) in older adults is estimated to have the potential to reduce total healthcare costs by $3.5 billion and total societal costs by $7.4 billion.

Weycker, Derek, Reiko Sato, David Strutton, John Edelsberg, Mark Atwood, et al. Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years. Vaccine. 2012; 30(36): 5437-44. http://www.sciencedirect.com/science/article/pii/S0264410X12008286

Reference

Title
Public Health and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine in U.S. Adults Aged > 50 Years
Publication
Vaccine
Publication Date
2012
Authors
Weycker, Derek, Reiko Sato, David Strutton, John Edelsberg, Mark Atwood, et al.
Volume & Issue
Volume 30, Issue 36
Pages
5437-44
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Polio vaccination prevented 5 million cases of paralysis since 1988
    Vaccination for polio reduced the number of worldwide cases from more than 300,000 per year in the 1980s to only 2,000 in 2002—also preventing an estimated 5 million cases of…  
  • Vaccines in development 2013
    Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.  
  • Cost effectiveness of MMR vaccine
    For every dollar spent on the MMR (measles, mumps, and rubella) vaccine, $21 is saved.  
  • Shingles vaccine reduces incidence by >50%
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the incidence of shingles by 51.3%.